An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An HPK1 inhibitor enhanced the tumour response to anti-PD-1 immunotherapy in non-Hodgkin’s lymphoma

Published:2023-04-27 Issue:7 Volume:23 Page:3767-3780
ISSN:1591-9528
Container-title:Clinical and Experimental Medicine
language:en
Short-container-title:Clin Exp Med

Author:

Yang Lin,Zhao Qiuling,Chen Ting,Liu Wenbin,Qiu Xiuliang,Chen Jincan,Huang Shengqiang,Huang Ruyi,Dong Liangliang

Funder

Natural Science Foundation of Fujian Province

Joint Funds for the innovation of science and Technology

Fujian Provincial Health Technology Project

Publisher

Springer Science and Business Media LLC

Subject

General Biochemistry, Genetics and Molecular Biology,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s10238-023-01068-3.pdf

Reference24 articles.

1. Zhang H, Dai Z, Wu W, et al. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer. J Exp Clin Cancer Res. 2021;40:184. https://doi.org/10.1186/s13046-021-01987-7.

2. Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153–67. https://doi.org/10.1038/nri.2017.108.

3. Xu-Monette ZY, Zhou J, Young KH. PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. Blood. 2018;131:68–83. https://doi.org/10.1182/blood-2017-07-740993.

4. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med. 2015;372:311–9. https://doi.org/10.1056/NEJMoa1411087.

5. Andorsky DJ, Yamada RE, Said J, et al. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells. Clin Cancer Res. 2011;17:4232–44. https://doi.org/10.1158/1078-0432.CCR-10-2660.

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Novel hematopoietic progenitor kinase 1 inhibitor KHK-6 enhances T-cell activation;PLOS ONE;2024-06-26

2. Current strategies for targeting HPK1 in cancer and the barriers to preclinical progress;Expert Opinion on Therapeutic Targets;2024-04-02

3. Discovery of 5-aminopyrido[2,3-d]pyrimidin-7(8H)-one derivatives as new hematopoietic progenitor kinase 1 (HPK1) inhibitors;European Journal of Medicinal Chemistry;2024-04

4. Unraveling the Role of the NLRP3 Inflammasome in Lymphoma: Implications in Pathogenesis and Therapeutic Strategies;International Journal of Molecular Sciences;2024-02-17

5. Progress in characterizing ABC multidrug transporters in zebrafish;Drug Resistance Updates;2024-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3